Cross-protection by MF59™-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses (original) (raw)
An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine
Daniela Toneatto
Vaccine, 2006
View PDFchevron_right
Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates
P. Durando
Vaccine, 2010
View PDFchevron_right
Immunogenicity and Safety of an MF59®-Adjuvanted and a Non- Adjuvanted Inactivated Subunit Influenza Vaccine in Adults Affected by Chronic Diseases
Vincenzo Baldo
Journal of Clinical Trials, 2012
View PDFchevron_right
Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 ® adjuvant
Frederic Clement
Human Vaccines & Immunotherapeutics, 2012
View PDFchevron_right
Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains
Barbara Camilloni
Immunity & ageing : I & A, 2014
View PDFchevron_right
MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk
P. Durando
Expert Opinion on Biological Therapy, 2010
View PDFchevron_right
Safety and immunogenicity of an MF59®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly
Giovanni Della Cioppa
Vaccine, 2012
View PDFchevron_right
Safety and Immunogenicity of Nonadjuvanted and MF59‐Adjuvanted Influenza A/H9N2 Vaccine Preparations
Dewei She
Clinical Infectious Diseases, 2006
View PDFchevron_right
Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity
V. La Fauci
Journal of preventive medicine and hygiene, 2009
View PDFchevron_right
Influenza vaccines: Antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population
Vincenzo Baldo
European Journal of Epidemiology, 1999
View PDFchevron_right
Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults
Frederic Clement
Human vaccines & immunotherapeutics, 2012
View PDFchevron_right
Response of Influenza Vaccines Against Heterovariant Influenza Virus Strains in Adults with Chronic Diseases
Tatjana Baldovin
Journal of Clinical Immunology, 2007
View PDFchevron_right
Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine
Tristan Morton Clark
New England Journal of Medicine, 2009
View PDFchevron_right
Immunogenicity of Three Different Influenza Vaccines against Homologous and Heterologous Strains in Nursing Home Elderly Residents
Silvia Majori, Tatjana Baldovin, Vincenzo Baldo
Clinical and Developmental Immunology, 2010
View PDFchevron_right
A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration
Giovanni Della Cioppa
Human Vaccines & Immunotherapeutics, 2014
View PDFchevron_right
Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis
Geert Leroux-Roels
Human vaccines & immunotherapeutics, 2016
View PDFchevron_right
Adjuvanted Influenza Vaccines Elicits Higher Antibody Responses against the A(H3N2) Subtype than Non-Adjuvanted Vaccines
Laura Sánchez de Prada
Vaccines
View PDFchevron_right
Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children
Terry Nolan
Vaccine, 2014
View PDFchevron_right
MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database
K. Lindert
Vaccine, 2009
View PDFchevron_right
Combined Administration of MF59-Adjuvanted A/H5N1 Prepandemic and Seasonal Influenza Vaccines: Long-Term Antibody Persistence and Robust Booster Responses 1 Year after a One-Dose Priming Schedule
Ralf Clemens
Clinical and Vaccine Immunology, 2013
View PDFchevron_right
A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59 ®
Karl-Heinz Herbinger
Human Vaccines & Immunotherapeutics, 2013
View PDFchevron_right
A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects
Geert Leroux-Roels
Vaccine, 2012
View PDFchevron_right
Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects
Mari Rose De los Reyes
Vaccine, 2014
View PDFchevron_right
MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18–60 years of age) with chronic diseases who are at risk of post-influenza complications
Vincenzo Baldo
Vaccine, 2007
View PDFchevron_right
A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59®-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects
Serhat Unal
View PDFchevron_right
Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials
Geert Leroux-Roels
Clinical and Vaccine Immunology, 2017
View PDFchevron_right